Avricore Health Inc.

The company's financials show resilient growth, with revenue advancing from $1.35M in Q4 2023 to $1.20M in Q3 2024. Gross profit remained healthy with margins at 36% in Q3 2024 compared to 37% in Q4 2023. Operating income hit -$173361.00 last quarter, sustaining a consistent -15% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$57629.00. Net income dropped to -$179015.00, while earnings per share reached -$0.002. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.